Porownywarka

Tesamorelin vs Ipamorelin side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

TesamorelinIpamorelin

Udostępnij porównanie peptydów

Wlasciwosc	Tesamorelin	Ipamorelin
Kategoria	Hormon wzrostu	Hormon wzrostu
Znany tez jako	Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8	IPAM, NNC 26-0161
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved) Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Visceral fat reduction, body composition, HIV lipodystrophy	Anti-aging, muscle building, sleep quality, recovery
Jak dziala	Tesamorelin is presented as a stabilized analog of GHRH 1-44. It acts at GHRH receptors upstream of direct growth-hormone replacement, prompting pituitary growth-hormone release and subsequent IGF-1 signaling. The source reports an N-terminal trans-3-hexenoic acid modification that slows enzymatic degradation, extending the signal relative to native GHRH. Trial-observed visceral-fat reductions are attributed to this growth-hormone-axis activity.	Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response.
Typowe dawkowanie	2 mg daily (F8: 1.28 mg daily) · Once daily · Subcutaneous injection in abdomen	200-300 mcg 2-3x daily · 2-3x daily
Dawkowanie z badań	2 mg once daily · Indefinite for approved indication · Subcutaneous injection	100-300 mcg per injection · 8-12 weeks typical · Subcutaneous injection
Typowy czas trwania	Indefinite for approved indication	8-12 weeks typical
Podanie	Subcutaneous injection	Subcutaneous injection
Timing	Before bed while fasted Take on empty stomach	Before bed or morning, fasted Fasted timing reported
Poziom dowodów	Zatwierdzone przez FDA	Badania kliniczne
Mozliwe skutki uboczne	Injection site reactions (Listed as common in the source.) Joint pain Peripheral edema (Swelling is also mentioned as a caution in the research summary.) +6 więcej Pain in extremities Muscle pain Increased diabetes risk (Source flags diabetes-related risk for review, especially in uncontrolled diabetes contexts.) May elevate blood glucose (Source notes possible blood-glucose elevation while also reporting no meaningful harm to blood-sugar control in the cited pivotal HIV trial.) Allergic reactions including anaphylaxis (Listed as rare in the source.) Increased IGF-1 (Mentioned in the source research summary as a possible growth-hormone-axis effect.)	Generally well tolerated (Reported by the source as a general tolerability statement, not a guarantee of safety.) Injection-site reactions Headache +6 więcej Nausea Increased appetite Water retention Temporary joint stiffness (Source describes joint stiffness as temporary.) No significant cortisol or prolactin elevation reported (Source presents this as a selectivity-related observation.) Contraindicated with active malignancy (Listed by the source as a contraindication.)
Podsumowanie researchu	The source describes an approval package grounded in randomized, placebo-controlled human studies. It specifically names Falutz and colleagues in a 2007 New England Journal of Medicine publication, reporting six-month visceral abdominal fat reduction in HIV patients, lipid-profile improvement, and no meaningful worsening of blood-sugar control. It also cites later randomized work, including a JAMA-published study led by Stanley, with reported reductions in visceral fat and liver fat. A smaller placebo-controlled study in non-HIV adults with abdominal obesity is described as showing visceral-fat reduction over 26 weeks, but the source frames that broader setting as less established than the HIV-associated indication. Reported cautions include joint pain, swelling, IGF-1 increases, cancer-history concerns, and uncontrolled diabetes concerns for growth-hormone-axis drugs.	The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes.
Referencje	New England Journal of Medicine JAMA +2 więcej PubMed Central ScienceDirect Topics	PubMed PubMed +1 więcej PubMed
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Tesamorelin

Ipamorelin

Kategoria

Hormon wzrostu

Znany tez jako

Egrifta, Egrifta WR, Egrifta SV, TH9507, Tesamorelin F8

IPAM, NNC 26-0161

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA Approved - HIV lipodystrophy (March 2025: F8 formulation approved)

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; Phase II trials discontinued. Listed as FDA Category 2 pending possible reclassification, with formal status not changed in the source.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Visceral fat reduction, body composition, HIV lipodystrophy

Anti-aging, muscle building, sleep quality, recovery

Jak dziala

Tesamorelin is presented as a stabilized analog of GHRH 1-44. It acts at GHRH receptors upstream of direct growth-hormone replacement, prompting pituitary growth-hormone release and subsequent IGF-1 signaling. The source reports an N-terminal trans-3-hexenoic acid modification that slows enzymatic degradation, extending the signal relative to native GHRH. Trial-observed visceral-fat reductions are attributed to this growth-hormone-axis activity.

Ipamorelin is reported to activate GHS-R1a, the ghrelin or growth hormone secretagogue receptor, on somatotroph cells in the anterior pituitary. The source links this receptor activity to Gq/phospholipase C signaling, IP3 generation, intracellular calcium release, and pulsatile release of stored growth hormone. It also describes ipamorelin as relatively selective in early characterization, with GH-releasing doses not meaningfully increasing ACTH, cortisol, prolactin, FSH, LH, or TSH. Because the mechanism relies on pituitary GH stores, the source indicates that pituitary function and normal feedback biology remain relevant to the response.

Typowe dawkowanie

2 mg daily (F8: 1.28 mg daily) · Once daily · Subcutaneous injection in abdomen

200-300 mcg 2-3x daily · 2-3x daily

Dawkowanie z badań

2 mg once daily · Indefinite for approved indication · Subcutaneous injection

100-300 mcg per injection · 8-12 weeks typical · Subcutaneous injection

Typowy czas trwania

Indefinite for approved indication

8-12 weeks typical

Podanie

Subcutaneous injection

Timing

Before bed while fasted

Take on empty stomach

Before bed or morning, fasted

Fasted timing reported

Poziom dowodów

Zatwierdzone przez FDA

Badania kliniczne

Mozliwe skutki uboczne

Injection site reactions (Listed as common in the source.)
Joint pain
Peripheral edema (Swelling is also mentioned as a caution in the research summary.)

+6 więcej

Pain in extremities
Muscle pain
Increased diabetes risk (Source flags diabetes-related risk for review, especially in uncontrolled diabetes contexts.)
May elevate blood glucose (Source notes possible blood-glucose elevation while also reporting no meaningful harm to blood-sugar control in the cited pivotal HIV trial.)
Allergic reactions including anaphylaxis (Listed as rare in the source.)
Increased IGF-1 (Mentioned in the source research summary as a possible growth-hormone-axis effect.)

Generally well tolerated (Reported by the source as a general tolerability statement, not a guarantee of safety.)
Injection-site reactions
Headache

+6 więcej

Nausea
Increased appetite
Water retention
Temporary joint stiffness (Source describes joint stiffness as temporary.)
No significant cortisol or prolactin elevation reported (Source presents this as a selectivity-related observation.)
Contraindicated with active malignancy (Listed by the source as a contraindication.)

Podsumowanie researchu

The source describes an approval package grounded in randomized, placebo-controlled human studies. It specifically names Falutz and colleagues in a 2007 New England Journal of Medicine publication, reporting six-month visceral abdominal fat reduction in HIV patients, lipid-profile improvement, and no meaningful worsening of blood-sugar control. It also cites later randomized work, including a JAMA-published study led by Stanley, with reported reductions in visceral fat and liver fat. A smaller placebo-controlled study in non-HIV adults with abdominal obesity is described as showing visceral-fat reduction over 26 weeks, but the source frames that broader setting as less established than the HIV-associated indication. Reported cautions include joint pain, swelling, IGF-1 increases, cancer-history concerns, and uncontrolled diabetes concerns for growth-hormone-axis drugs.

The source identifies Raun et al. 1998 as early foundational work and describes characterization across rats, pigs, and isolated pituitary cells. It reports that ipamorelin released GH without corresponding ACTH or cortisol increases at doses above the GH-release threshold. The source also notes that human development reached Phase II for postoperative ileus before being discontinued for insufficient efficacy. For popular wellness uses such as anti-aging, fat loss, muscle gain, or recovery, the source states that large peer-reviewed human randomized trials are not available and that these claims are extrapolated from mechanism rather than established outcomes.

Referencje

New England Journal of Medicine JAMA

+2 więcej

PubMed Central ScienceDirect Topics

PubMed PubMed

+1 więcej

PubMed

Pełny profil

Zobacz szczegóły